Bluenote Raises $10M to Expand Generative AI Platform for Life Sciences

Company Name: Bluenote
Location: San Francisco, CA
Industry: Generative AI for Life Sciences

Funding Details:

Amount: $10M
Investors: Lux Capital (Lead), Elad Gil, Anthropic, Menlo Ventures Anthology Fund, McKesson Ventures, Avichal Garg/Electric Capital, Moxxie Ventures, Carbon Silicon Ventures, and prominent leaders in AI and life sciences including Othman Laraki (CEO Color Health), Fidji Simo (CEO Instacart), Mike Nohaile (CEO Prellis Biologics), Kristen Fortney (CEO BioAge), Eric Morgen (COO BioAge), Qasar Younis (CEO Applied Intuition), Linus Upson (Verily), and Jeffrey Low.

Purpose of Investment:
The funds will be used to expand Bluenote’s generative AI platform to support additional workflows for life sciences companies.

Leadership:
Co-Founders: Fatima Sabar, Katsuya Noguchi

Product:
Bluenote’s generative AI platform accelerates regulatory and operational workflows for life sciences companies, enabling faster innovation delivery to patients. Key applications include:

• Regulatory Filings & Technical Reports: Automating complex documentation processes.
• Standard Operating Procedures (SOPs): Streamlining protocol and validation report creation.
• Risk Analyses & Manufacturing Documentation: Enhancing compliance and operational efficiency.

The platform has already deployed 15+ applications tailored for scientists, engineers, quality, regulatory, and manufacturing teams, driving efficiency and innovation across the life sciences ecosystem.

About the Company:
Bluenote is transforming the life sciences industry with AI-powered solutions that simplify and optimize critical workflows. By reducing the time and complexity of regulatory and operational tasks, the platform helps life sciences companies bring their innovations to patients faster.

With strategic investment and a clear growth trajectory, Bluenote is positioned to lead the future of generative AI applications in life sciences.